Prognostic Value of the Baseline Systemic Immune-Inflammation Index in HER2-Positive Metastatic Breast Cancer: Exploratory Analysis of Two Prospective Trials
Authors:
- 20 November 2024
- journal article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (2) , 750-759
Abstract
The systemic immune-inflammation index (SII) is a hematological marker that reflects the immune status of the body. This study was designed to evaluate theKeywords
Funding Information
- the Cutting-edge Cancer Support Treatment Research Project (CPHCF-2023-023)
- Scientific Research Project of Hunan Provincial Health Commission (D202302066995)
- the Changsha Natural Science Foundation project (kq2007058)
- Beijing Medical Award Foundation-China Endocrine Targeted Therapy Research Fund for Advanced breast cancer (YXJL-2020-0941-0747)
This publication has 29 references indexed in Scilit:
- Increased systemic immune-inflammation index independently predicts poor survival for hormone receptor-negative, HER2-positive breast cancer patientsCancer Management and Research, 2019
- Prognostic Value of Preoperative Systemic Immune-Inflammation Index in Patients with Cervical CancerScientific Reports, 2019
- HER2-positive breast cancerThe Lancet, 2017
- 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trialThe Lancet, 2017
- Platelets at the interface of thrombosis, inflammation, and cancerBlood, 2015
- Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular CarcinomaClinical Cancer Research, 2014
- Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patientsAnnals of Oncology, 2014
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast CancerNew England Journal of Medicine, 2012
- Neutrophil elastase–mediated degradation of IRS-1 accelerates lung tumor growthNature Medicine, 2010
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001